Fixed-duration therapy achieved deeper remissions, with undetectable MRD in 73.3% of patients treated with venetoclax-obinutuzumab and 47.2% of those treated with venetoclax-ibrutinib. For patients ...
Please provide your email address to receive an email when new articles are posted on . Azacitidine plus venetoclax significantly improved EFS compared with induction chemotherapy for certain patients ...
Continuous and fixed-duration treatments result in similar outcomes for chronic lymphocytic leukemia
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed ...
ORLANDO -- A year of combination therapy for previously untreated chronic lymphocytic leukemia (CLL) patients led to similar outcomes compared with indefinite BTK inhibition with ibrutinib (Imbruvica) ...
Those assigned to the "I" arm received continuous ibrutinib (a BTK inhibitor) indefinitely unless they experienced disease progression or unacceptable side effects. Those in the "VO" arm received 12 ...
ORLANDO, Fla., Dec. 6, 2025 /PRNewswire/ -- Four clinical trials to be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition illustrate how advancements in ...
Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches — continuous therapy with Bruton’s tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax ...
Ashwagandha is generally safe and well-tolerated, but may have side effects like nausea, vomiting, drowsiness, and headaches. More serious side effects can include liver problems, increased thyroid ...
Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...
Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed ...
Decitabine/cedazuridine plus venetoclax met its primary endpoint with a complete response rate of 46.5%. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA ...
The phase 3 VERONA trial did not meet the primary endpoint of overall survival. Topline data were announced from a phase 3 trial evaluating venetoclax (Venclexta ®) plus azacitidine for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results